Fiorentino D, Mangold AR, Werth VP, Christopher-Stine L, et al. Efficacy, safety, and target engagement of dazukibart, an IFNbeta specific monoclonal antibody, in adults with dermatomyositis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial. Lancet 2025;405:137-146.
PMID: 39798982